Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yasumasa Kakei has a total of 374 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Specialty-stratified trends in oral cancer resection in Japan before, during, and after the COVID-19 pandemic: A National Database analysis (2016–2023) with comparative context from Germany

    by Yasumasa Kakei, Robert Sader, Tatsuya Furukawa, Hirotaka Shinomiya, Masaya Akashi, Takeshi Fujita, Kensuke Yamauchi, Philipp Thoenissen

  • Open Access

    Risk factors and treatment outcomes of metachronous isolated distant metastasis in oral squamous cell carcinoma: A multicenter retrospective cohort study in Japan

    by Yasumasa Kakei, Takumi Hasegawa, Takumi Imai, Hiroshi Nakamura, Nobuhiro Yamakawa, Yusuke Yokota, Masaya Okura, Tomofumi Naruse, Hiroshi Kurita, Eiji Hirai, et al.

  • Open Access

    Expression of Mitophagy-Associated Factors and Their Associations with Metastasis and Prognosis in Oral Squamous Cell Carcinoma

    by Yudai Matsuzoe, Daisuke Takeda, Izumi Saito, Yuki Murakami, Aki Murakami, Yoshiaki Tadokoro, Junya Hirota, Yasumasa Kakei, Masaya Akashi, Takumi Hasegawa

    Background/Objectives: Mitophagy-associated factors have been implicated in tumor behavior and patient outcomes; however, their clinical significance depends on tumor type, stage, and microenvironmental context, and consistent conclusions remain lacking. We aimed to comprehensively assess the expression of mitophagy-associated factors in a moderate-sized cohort of patients with oral squamous cell carcinoma (OSCC) and clarify their prognostic significance. Methods: A retrospective cohort study included 197 patients with OSCC who underwent primary surgical resection between August 2013 and October 2018. Immunohistochemical expression of mitophagy-associated factors, including transcription factor EB (TFEB), nuclear factor erythroid 2-related factor 2 (NRF2), activating transcription factor 4 (ATF4), Parkin, PTEN-induced kinase 1 (PINK1), and mitochondrial ubiquitin ligase (MITOL), was evaluated. Associations between protein expression and clinicopathological parameters, local control, 5-year disease-specific survival (DSS), regional control, and distant metastasis were analyzed. Results: High expression of NRF2 and TFEB was significantly related with decreased DSS, poor regional control, and increased distant metastasis. High ATF4 expression was associated with distant metastasis and showed no association with DSS. Parkin, PINK1, and MITOL showed no significant association with patient outcomes. Explanatory multivariable analysis showed associations between high TFEB expression, vascular invasion, extranodal extension, and disease-specific mortality. Conclusions: TFEB expression showed an exploratory association with aggressive tumor behavior and poor prognosis in OSCC, warranting further investigation. However, because immunohistochemical evaluation measures protein expression rather than mitophagy flux or mitochondrial turnover, these findings represent associations between mitophagy-associated factor expression and clinical outcomes and do not directly demonstrate altered mitophagy activity.

  • Open Access

    Comparative economic burden of craniomaxillofacial trauma surgery in Japan and Germany: a national database analysis with a health insurance system perspective

    by Yasumasa Kakei, Robert Sader, Masaya Akashi, Kensuke Yamauchi, Philipp Thoenissen

    Objectives: To estimate and compare the socioeconomic burden of craniomaxillofacial (CMF) trauma surgery in Japan and Germany across the prepandemic, pandemic, and postpandemic periods, considering each country’s health insurance system. Methods: We performed a secondary analysis integrating two national database studies. Japanese data (NDB; K-code and J-code billing, 2016–2023, 49,379 procedures) were combined with German data (InEK; 2019–2023, approximately 440,000 diagnoses). Costs were calculated using Japan’s fee-for-service schedule and the German DRG (G-DRG) system. Importantly, the Japanese dataset enumerates surgical procedures, whereas the German dataset enumerates inpatient diagnoses; this fundamental difference in unit of measurement must be considered when interpreting all comparative results below. Results: In Japan, annual direct surgical cost averaged ¥1,061.7 million ($7.08M USD) prepandemic, declining 19.19 % to ¥858.0 million during the pandemic, with a small persistent postpandemic gap (−1.69 %). In Germany, annual inpatient CMF costs totaled €181.2 million prepandemic, declining by 19.24 % to €146.3 million. Patient copayments differed markedly: Japanese patients bore 30 % of costs (¥48,608/case), vs. approximately €40/case in Germany. Conclusions: Despite different financing models, both countries showed strikingly similar pandemic-related cost reductions (Japan −19.19 %, Germany −19.24 %). Japan’s fee-for-service model creates greater revenue sensitivity to volume changes, whereas the G-DRG system provides partial buffering. The pronounced per-case copayment disparity (approximately 7.5-fold higher in Japan in USD terms) raises questions about healthcare equity, though any effect on care-seeking behavior remains speculative. As the Japanese and German data sources reflect surgical procedures and clinical diagnoses, respectively, these findings are not directly volume-equivalent and should be interpreted accordingly.

  • Open Access

    Clinical Evaluation of Polyglycolic Acid Sheet Application After Partial Glossectomy: A Retrospective Analysis of 284 Consecutive Cases

    by Yasumasa Kakei, Kaito Uryu, Masatoshi Toshikawa, Takumi Imai, Takumi Hasegawa, Masaya Akashi

    Objective: To evaluate the clinical outcomes of polyglycolic acid (PGA) sheet application with fibrin glue after partial glossectomy, comparing Neoveil and Neoveil Nano sheets, and to identify factors affecting sheet detachment, postoperative bleeding, and granuloma-like neoplasm (GLN) development. Study design: We retrospectively analyzed 284 consecutive patients who underwent partial glossectomy with PGA sheet coverage between February 2011 and November 2025. Two sheet types were used: Neoveil (n = 169) and Neoveil Nano (n = 115). The primary outcome was sheet detachment; secondary outcomes were postoperative bleeding and GLN development. Multivariable modified Poisson regression was performed. Results: The overall engraftment rate was 81.3% (231/284). Neoveil Nano showed significantly higher engraftment (98.3%) than Neoveil (69.8%). Multivariable analysis revealed that Neoveil Nano (risk ratio (RR) = 0.079, 95% confidence interval (CI): 0.019-0.325, P < 0.001) and electrical scalpel use (RR = 0.468, 95% CI: 0.268-0.819, P = 0.008) were independent protective factors against detachment. Postoperative bleeding occurred in 6.3% (18/284). GLN developed in 10.9% (31/284), with a median onset of 53.0 days. Patients with wound-healing-impaired conditions showed a numerically higher GLN rate (17.0% vs 9.7%) and earlier onset. Conclusions: Neoveil Nano PGA sheets demonstrate superior engraftment compared with conventional Neoveil after partial glossectomy. Electrical scalpel resection also improves engraftment. Sheet detachment was strongly associated with postoperative bleeding, highlighting the importance of sheet adhesion during early wound healing.

  • Open Access

    Three-dimensional finite element analysis for internal fixation of mandibular condylar fractures: a scoping review

    by Yasumasa Kakei, Robert Sader, Philipp Ebener, Atsuki Tanaka, Masaya Akashi, Ryosuke Kuroda, Philipp Thoenissen

    Purpose: Three-dimensional finite element analysis (3D-FEA) has emerged as an essential computational tool for evaluating the biomechanical behaviors of internal fixation systems for mandibular condylar fractures. This scoping review maps and synthesizes the existing literature on 3D-FEA studies investigating the internal fixation of mandibular condylar fractures and explores, in a descriptive manner, differences in methodological focus between European and non-European research centers. Methods: PubMed and Cochrane Library databases were systematically searched following PRISMA-ScR guidelines. Original English-language research articles using 3D-FEA to evaluate internal fixation of mandibular condylar fractures were included. Data were extracted using a standardized charting form. Results: Thirty-six studies met the inclusion criteria. European studies ( n = 12) predominantly focused on development of novel plate designs and mechanical testing protocols, whereas Asian and other nationality studies ( n = 24) emphasized material comparisons between titanium and bioabsorbable systems, patient-specific modeling, and loading condition analysis. Consensus findings include: (1) double-plate fixation provides superior stability; (2) among 3D plate designs, trapezoid plates demonstrate the best performance for subcondylar and condylar base fractures, whereas alpha and lambda plates may be preferable for condylar neck fractures; (3) plate positioning along the posterolateral ramus border and anterolateral sigmoid notch (A+B configuration) offers optimal biomechanical performance; and (4) contralateral molar clenching produces the highest stress concentrations. Conclusion: Across the included FEA studies, the A+B double-plate configuration was the most consistently reported biomechanically favorable approach for both titanium and bioabsorbable systems; the trapezoid plate performed best for subcondylar and condylar base fractures, and two-screw osteosynthesis was effective for condylar head fractures. As these findings derive from computational models, clinical validation remains necessary. Future research should focus on patient-specific modeling, clinical outcome validation, and standardization of methodological protocols.


  • Open Access

    Phase I Pilot Study of a Novel Celecoxib-Containing Paste for Local Application Following Mandibular Third Molar Extraction: Safety, Tolerability, and Feasibility of a Dose-Escalation Design

    by Yasumasa Kakei, Masaya Akashi, Takumi Hasegawa, Takeshi Ioroi, Ikuko Yano

    Background and objectives: Postoperative pain after mandibular third molar extraction remains a significant clinical challenge. Local drug delivery to the extraction socket may enable targeted analgesia with minimal systemic exposure. This first-in-human pilot study aimed to evaluate the safety and tolerability of a novel celecoxib-containing paste applied to extraction sockets and to assess the feasibility of the dose-escalation design, outcome measures, and study procedures to inform a future definitive randomized controlled trial. Methodology: This single-center, open-label, dose-escalation study enrolled 18 adult patients undergoing mandibular third molar extraction in three sequential cohorts (n = 6 each): low (0.5 mg/mL), medium (1.0 mg/mL), and high (2.0 mg/mL) celecoxib paste. Following extraction, 1-2 mL of paste was applied to the socket. The primary safety outcome was the incidence of alveolar osteitis (dry socket) by day 8. Feasibility outcomes included recruitment and retention rates, protocol adherence, and the performance of exploratory efficacy measures, including the visual analog scale (VAS) pain scores, rescue analgesic consumption, and patient-reported effectiveness. The study followed the Consolidated Standards of Reporting Trials (CONSORT) extension for pilot and feasibility trials, adapted for a non-randomized design. Results: All 18 participants completed the study with no withdrawals (retention rate: 100%). No cases of dry socket or treatment-related adverse events were observed (0/18; 95% CI: 0-15.3%). Mean VAS pain scores declined consistently across all cohorts from days 1 to 5. Higher-dose groups showed numerically greater reductions in rescue analgesic consumption. The dose-escalation protocol, outcome measures, and data collection procedures were feasible and performed as intended. Conclusions: Application of celecoxib-containing paste to extraction sockets was well tolerated without dry socket or other safety concerns. The study procedures were feasible, and preliminary efficacy signals support progression to a larger, randomized, placebo-controlled trial. Trial registration: Japan Registry of Clinical Trials (jRCT; https://jrct.niph.go.jp/; identifier: jRCT2051230162). Registered on January 11, 2024.

  • Open Access

    Phase I Study of B440, an Oral Wilms' Tumor 1 Cancer Vaccine Using a Bifidobacterium Vector, in Patients With Metastatic Urothelial Cancer

    by Hideto Ueki, Junya Furukawa, Takuto Hara, Keisuke Goto, Keita Tamura, Yuto Matsushita, Yasumasa Kakei, Sae Murakami, Naoe Jimbo, Jun Teishima, et al.

    PURPOSE: Immune checkpoint inhibitors (ICIs) demonstrate limited efficacy in metastatic urothelial cancer (mUC), with most patients eventually developing resistance. B440 is an oral cancer vaccine composed of recombinant Bifidobacterium engineered to express the Wilms' tumor 1 (WT1) tumor-associated antigen, designed to elicit tumor-specific T-cell responses via gut-associated lymphoid tissue. This phase I study evaluated the safety, preliminary efficacy, and immunogenicity of B440 in patients with mUC refractory to standard therapies. METHODS: Twelve patients with mUC who had progressed after platinum-based chemotherapy, PD-1/PD-L1 inhibitors, and enfortumab vedotin received oral B440 at either 800 mg (n = 6) or 1,600 mg (n = 6) once daily for five consecutive days per week over 4 weeks. The primary end point was dose-limiting toxicity (DLT). Secondary end points included safety, best overall response, and progression-free survival (PFS). WT1-specific T-cell responses were assessed via interferon-γ enzyme-linked immunospot (ELISPOT) assays. Fecal samples were collected for gut microbiome analysis. RESULTS: No DLTs were observed. Treatment-related adverse events were mild (grade 1), with transient IL-6 elevations reported in three patients. The disease control rate was 50%, with six patients achieving stable disease. WT1-specific T-cell responses were detected in six patients, who showed numerically longer PFS than ELISPOT-negative patients (117 v 37 days; nominal P = .030, uncorrected for multiple comparisons). Changes in gut microbiome diversity showed exploratory associations with clinical outcomes. CONCLUSION: B440 was safe and well tolerated. WT1-specific immune responses correlated with clinical benefit, supporting further investigation of B440 in combination immunotherapy trials.


  • Segmental mandibulectomy for osteonecrosis of the jaw: A comparison of patients with and without reconstruction

    by Yujiro Hiraoka, Yoshitaka Nakahira, Kaito Uryu, Daisuke Takeda, Yasumasa Kakei, Akira Kimoto, Takumi Hasegawa, Masaya Akashi

  • Four-year neurodevelopmental outcomes in infants with symptomatic congenital cytomegalovirus disease treated with oral valganciclovir: A prospective follow-up study in Japan

    by Yasumasa Kakei, Ichiro Morioka, Takumi Imai, Aya Okahashi, Kazumichi Fujioka, Kandai Nozu, Tetsushi Yoshikawa, Hiroyuki Moriuchi, Yu Kakimoto, Yoshinori Ito, et al.